News | December 03, 2008

St. Jude Launches QuickOpt Timing Cycle Optimization for Defibrillators in Japan

December 4, 2008 - St. Jude Medical Inc. this week said it received expanded approval from the Japanese Ministry of Health, Labour and Welfare for the QuickOpt Timing Cycle Optimization feature in the Epic HF and Atlas HF cardiac resynchronization therapy defibrillators (CRT-Ds).

CRT-Ds are implantable cardioverter defibrillators (ICDs) that help prevent sudden cardiac arrest and treat heart failure by synchronizing heart rhythms. The QuickOpt capability allows physicians to easily test and optimize a patient’s CRT-D to ensure that its pacing rhythm is customized to the individual patient’s needs. This is important because heart disease is different in each patient, so optimizing the devices helps to ensure that each patient receives the full benefit of device therapy.

Optimized timing can increase the efficiency of the heart’s ability to pump blood to the body. The company said at a fraction of the time and cost of conventional echocardiogram-based optimizations, the QuickOpt feature can help physicians optimize more patients in less time through a simple procedure. In 90 seconds during a regular follow-up visit, the QuickOpt feature can recommend the optimal A-V (atrial-ventricular) and V-V (ventricular-ventricular) timing values to use in programming the devices.

“QuickOpt optimization gives me the ability to precisely program the device to meet each patient’s specific needs for treating their heart failure,” said Hiroshi Nakajima, M.D., of Itabashi Chuo Medical Center. “It allows me to check my patients’ devices and adjust the timing whenever needed so that the therapy can be continuously optimized for each patient.”

Traditional echocardiography (echo), while considered the gold standard for optimizing devices, can be expensive and time-consuming. The company said QuickOpt feature produces results clinically proven to be comparable with those of echo, in 90 seconds instead of the 30 to 120 minutes required for a typical echo.

For more information:

Related Content

Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT)| August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
The FDA is concerned about cybersecurity of ICDs and cyber security of other medical devices.
Feature | Cybersecurity| August 16, 2017 | Dave Fornell
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Merge Hemo cath lab hemodynamics monitoring system.

Hemodynamic data shown on screens from the Merge Hemo recording system. It is among the newer generation hemodynamic systems for cath labs that are more user friendly and have technologies to speed workflow.

Feature | Hemodynamic Monitoring Systems| August 03, 2017 | Dave Fornell
The current generation of...
Left Atrial Pressure Monitor from Vectorious Medical Technologies Offers New Hope for Heart Failure Patients

On of the top stories in July was the introduction of a left atrial pressure monitor from Vectorious Medical Technologies to prevent heart failure patient hospitalizations or readmissions. Read the article"Left Atrial Pressure Monitor Offers New Hope for Heart Failure Patients."

Feature | August 01, 2017 | Dave Fornell
Ohio State Researchers Prove Human Heart's 'Battery' Has Multiple Backups
News | EP Lab| July 27, 2017
July 27, 2017 — There is good news when it comes to the heart’s sinoatrial node (SAN), the body’s natural...
Medtronic Announces First Enrollments in STOP AF First Clinical Trial
News | Ablation Systems| July 24, 2017
Medtronic plc recently announced first enrollments in the STOP AF First clinical trial. The trial will evaluate the...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT)| July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Overlay Init